{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-26-000047","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2026-08-04T12:02:40+00:00","discovered_at":"2026-08-04T12:05:00.378388+00:00","generated_at":"2026-08-04T12:05:04.276130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Exagen Q2 2026: record revenue $19.9M (+16% YoY), net loss narrowed, guidance raised","bullets":["Revenue $19.9M, up 16% YoY; net loss $3.2M vs $4.4M in Q2 2025, improved 28%.","Adjusted EBITDA loss narrowed to $0.1M from $1.7M; operating loss $1.7M vs $2.6M.","AVISE CTD test volume +11% YoY; trailing 12-month ASP $446, up $18 (+4%).","Full-year 2026 revenue guidance raised to $72-75M from prior $70-73M.","Cash $24.6M; published study showing AVISE Lupus identified ~25% of SLE patients missed by conventional markers."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-26-000047","json":"https://secwatch.observer/filing/0001274737-26-000047.json","markdown":"https://secwatch.observer/filing/0001274737-26-000047.md","text":"https://secwatch.observer/filing/0001274737-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/0001274737-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/exdx-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T12:05:04.276130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}